Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
103.20    0.00 (0.00%)
Bid:
82.00
Ask:
0.00
Spread: 22.20 (27.073%)
Market Cap: £169.19m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Trading Update

15 May 2008 07:00

RNS Number : 4877U
Yule Catto & Co PLC
15 May 2008
Β 

ο»Ώ

Yule Catto & Co plcΒ 

AGMΒ Statement and Trading Update

At today's Annual General Meeting of Yule Catto & Co plc to be held at 12.00Β noon at Saddlers' Hall, 40 Gutter Lane,Β LondonΒ EC2V 6BR, Anthony Richmond-Watson, Chairman, will make the following statement,Β which comprises Yule Catto's Interim Management Statement for the period from 1 January 2008 to date.

"2007 was a good year for the Group. We made steady progress across all of our divisions in both our operational performance and strategic plans to develop the Group for the future. This showed through in the financial results.

"The Polymers business had another good year of growth in volumes and profit. Our strategy in Polymers remains focused on geographical expansion around our existing business hubs and developing market sectors where our product technology and manufacturing capabilities give us real competitive advantage. We are investing heavily in additional Nitrile capacity inΒ MalaysiaΒ to take full advantage of the continued growth in this product and the Asian region.

"Our Pharma business continued to grow the range of generic and ethical products that it plans to manufacture by registering further drug master files in the year. As we had previously indicated Pharma earnings declined, in part due to the phasing of orders in the second half of the year. We announced plans to exit our Italian site to improve the operational cost base and the productivity of the business. This exit is proceeding to plan.

"Impact Chemicals has had a challenging year, but has delivered significant improvement. We are clearly seeing the benefits of our strategy to raise the performance of these businesses through restructuring and focussing on market segments offering better margins and growth.

"Overall, underlying Group profit before taxation increased some 10% to Β£34.5 million, and earnings per share by 18% to 17.3 pence per share.

"This has been a year in which much has been achieved. On behalf of the directors and shareholders, I would like to thank all our employees everywhere for their commitment and contribution towards the company's success.

Management Changes

"Alan Maddy, Chief Executive of the Polymer Division,Β will be retiringΒ in AugustΒ this year afterΒ 38Β years with the Group. He is replaced by Derick Whyte, who was previously CEO of the Impact Division. Adrian Whitfield has assumed direct management control of the Impact businesses.

Board Changes

"David Blackwood joined the Group and the Board as Finance Director in October last year. Sandy Dobbie and Jez Maiden were appointed independent non-executive directors in August; their appointments arise out of our regular reviewΒ of the board's composition. In the coming year we expect to address such issues further.

As far as my position as Chairman is concerned, I have decided that now is an appropriate time for the Board to initiate a process to appoint my successor.

"Messrs. Blackwood, Dobbie and Maiden seek election today having been appointed since the 2007 AGM. Dato' Seri Lee Oi Hian,Β Dato' Lee Hau Hian, Alex Catto and myself are also standing for re-election at today's meeting

Interim Management Statement

"2008Β has started positively, with our un-audited management accounts showing revenues and profits in-line withΒ ourΒ expectationsΒ and ahead of last year.

"Polymer ChemicalsΒ madeΒ aΒ solidΒ start to the year,Β ahead on sales and profit, supportedΒ byΒ the expandedΒ nitrileΒ capacity inΒ Malaysia,Β whereΒ weΒ remain on track to further expand nitrile capacity byΒ approximatelyΒ 60%Β during the second halfΒ of the year.

"PharmaΒ ChemicalsΒ experienced a very strong first halfΒ in 2007Β based in theΒ mainΒ on customer orderΒ phasing. Profit for the first quarterΒ of this yearΒ isΒ consequently below last year, butΒ the results are in line with our expectations.

"The results for ImpactΒ ChemicalsΒ areΒ ahead of last yearΒ as expected, benefitting from the restructuring programme.Β We have implemented further restructuring at William Blythe in the first quarter, and results there shouldΒ furtherΒ improve through the rest of the year.

"Overall the year has started well, though we see general signs of economic weakness around the world. We remain focused on deliveringΒ valueΒ from the Impact portfolio andΒ improvingΒ the Pharma businessΒ throughΒ the Italian site restructuring programme.Β The Polymers business has made aΒ solidΒ start to the year, and shouldΒ showΒ further improvement again this year.Β Overall, despiteΒ the economicΒ concernsΒ we remain confident thatΒ 2008 will be a year of further improvement for the Group."Β 

15 May 2008

ENQUIRIES:

YULE CATTOΒ 

Tel: 01279 442791

Adrian Whitfield, Chief ExecutiveΒ 

David Blackwood, Finance DirectorΒ 

Β 

COLLEGE HILLΒ 

Tel: 020 7457 2020Β 

Gareth David

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTAIMFTMMABBIP
Date   Source Headline
2nd Jan 20259:00 amRNSDirectorate Change
31st Oct 20247:00 amRNSTrading statement - Autumn 2024
17th Oct 20244:01 pmRNSHolding(s) in Company
14th Oct 20241:51 pmRNSHolding(s) in Company
27th Sep 202412:46 pmRNSHolding(s) in Company
19th Sep 20241:01 pmRNSHolding(s) in Company
13th Aug 20247:00 amRNSInterim results
18th Jul 202412:53 pmRNSChair succession and other board changes
17th May 20248:20 amRNSPost Stabilisation Notice
9th May 20242:29 pmRNSResults of AGM
9th May 20247:00 amRNSTrading Statement - Spring 2024
1st May 20247:00 amRNSDivestment of Compounds completed
25th Apr 20244:30 pmRNSDirector/PDMR Shareholding
25th Apr 20244:20 pmRNSDirector/PDMR Shareholding
17th Apr 202410:43 amRNSTender offer results
15th Apr 20247:00 amRNSDivestment of Compounds
12th Apr 20247:00 amRNSPricing of senior notes
9th Apr 20243:47 pmRNSPre Stabilisation Notice
9th Apr 20248:09 amRNSNotice of tender offer
9th Apr 20248:09 amRNSProposed offering of senior notes
28th Mar 20242:38 pmRNSDirector/PDMR Shareholding
28th Mar 20242:38 pmRNSDirector/PDMR Shareholding
28th Mar 20242:10 pmRNSAnnual Financial Report and Notice of AGM
12th Mar 20247:00 amRNSFinal Results
30th Jan 20247:00 amRNSTrading Statement
17th Jan 20242:58 pmRNSExternal Appointment
15th Nov 20237:00 amRNSTrading statement - Autumn 2023
3rd Nov 20232:54 pmRNSDirector/PDMR Shareholding
23rd Oct 20231:58 pmRNSDirector/PDMR Shareholding
18th Oct 20237:00 amRNSDirector/PDMR Shareholding
17th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20233:13 pmRNSHolding(s) in Company - CORRECTION
16th Oct 202312:06 pmRNSHolding(s) in Company
16th Oct 202312:03 pmRNSHolding(s) in Company
16th Oct 202311:57 amRNSHolding(s) in Company
16th Oct 20237:00 amRNSTotal Voting Rights
16th Oct 20237:00 amRNSPDMR and PCA Notification
13th Oct 20234:18 pmRNSHolding(s) in Company
13th Oct 202310:48 amRNSHolding(s) in Company
13th Oct 20237:00 amRNSResult of rump placing
12th Oct 20234:36 pmRNSResult of Equity Issue
12th Oct 202310:09 amRNSHolding(s) in Company
11th Oct 20239:39 amRNSHolding(s) in Company
11th Oct 20237:00 amRNSPDMR PCA Notification
10th Oct 20233:04 pmRNSHolding(s) in Company
10th Oct 202310:26 amRNSHolding(s) in Company
10th Oct 202310:26 amRNSHolding(s) in Company
9th Oct 20233:08 pmRNSHolding(s) in Company
9th Oct 20239:44 amRNSHolding(s) in Company
6th Oct 20231:56 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.